Tumour agnostic drugs

Description

Article on the development of new targeted drugs capable of treating multiple different tumour types based on presence of a common genetic alteration. Main focus on NTRK and microsatellite instability. Raises challenges associated with obtaining approvals for such drugs particularly if alterations are uncommon and difficulty in obtaining randomised controlled data for comparisons with standard of care